Novoridge

Integrated Drug Discovery

NOVORIDGE is a chemistry-focused CRO organization in India and provides innovative drug discovery services to leading pharmaceutical companies, including biotech firms, and academic institutions through our location in India and Korea. We provide fully customizable and tailored solutions to suit your specific needs, whether you require a stand-alone project or comprehensive integrated drug discovery services. Our capabilities extend from initial concept to candidate selection. information.

We can also optimize your lead compound whether it’s small molecules, or peptide and TPD for therapeutics or diagnostic drug candidate. We work closely with you to synthesize libraries that optimize structure-activity relationships. We also synthesize new molecules based on your lead, allowing for in vitro to identify further drug candidates. All intellectual property generated through our collaboration is owned by customer. Contact us for further information.

Target Identification	Hit to Lead approaches	Lead Discovery	Lead Optimization	Preclinical Studies
Medicinal Chemistry in Drug Discovery
Virtual screening De novo design Machine learning approach Or Your Hit Target small molecules or peptides	Structure / Fragment based approaches Focused library design and synthesis Library series categorization / prioritization	Design core, focused library and synthesis Docking scoring Scaffold hoping	QSAR Focused library design and synthesis Structure based optimization Back-up and scale-up strategy	In silico ADMET predictions Physiologically-based pharmacokinetics (PBPK) simulation
Radiopharmaceutical & Theranostics precursor development
Virtual screening De novo design Machine learning approach Or Your Hit Target small molecules or peptides	Focused library design and synthesis Design parameters for rational PET ligand Design Understand the target (Bmax and bio-distribution)	Design core, focused library and synthesis Structure handle for 18F or 11C labelling Amenable for late-stage radiolabelling	Optimized protecting/leaving group for radiolabelling Develop and synthesis precursor for radiolabelling Synthesis reference standards	Pharmacology High Potency High selectivity PK properties Brain permeability Low non-specific binding (NSB) Safe for clinical dosing and micro dosing GLP

Target Identification

Hit to Lead approaches

Lead Discovery

Lead Optimization

Preclinical Studies

Medicinal Chemistry in Drug Discovery

Virtual screening
De novo design
Machine learning approach Or Your Hit Target small molecules or peptides

Structure / Fragment based approaches
Focused library design and synthesis
Library series categorization / prioritization

Design core, focused library and synthesis
Docking scoring
Scaffold hoping

QSAR
Focused library design and synthesis
Structure based optimization
Back-up and scale-up strategy

In silico ADMET predictions
Physiologically-based pharmacokinetics (PBPK) simulation

Radiopharmaceutical & Theranostics precursor development

Virtual screening
De novo design
Machine learning approach Or Your Hit Target small molecules or peptides

Focused library design and synthesis
Design parameters for rational PET ligand Design
Understand the target (Bmax and bio-distribution)

Design core, focused library and synthesis
Structure handle for 18F or 11C labelling
Amenable for late-stage radiolabelling

Optimized protecting/leaving group for radiolabelling
Develop and synthesis precursor for radiolabelling
Synthesis reference standards

Pharmacology

High Potency
High selectivity

PK properties

Brain permeability
Low non-specific binding (NSB)

Safe for clinical dosing and micro dosing GLP

Integrated Drug Discovery

Medicinal Chemistry in Drug Discovery

Radiopharmaceutical & Theranostics precursor development

Headquarter

India

South Korea

Heakjeong Lee

Japan

Tatsuo Ido, Ph.D.

New Zealand & Australia

Mohammad Qasim, Ph.D.

Quick Links

Follow us